PI (Principal Investigator)
Prof. Reinhard Dummer
Melanom – in Behandlung mit BRAF/MEK-Inhibitoren +/- Immuntherapie
Melanom-Patienten derzeit in Behandlung mit BRAF/MEK-Inhibitoren +/- Immun-therapie
anti-IL6 Therapie
IIT Pyrexia-Management
NCT04652258
A phase II, open label, single arm, single center study to evaluate pyrexia management (with or without any other cytokine release symptoms) using tocilizumab, an humanized monoclonal antibody against the Interleukin – 6 Receptor in melanoma patients treated with BRAF/MEK inhibitors and/or immunotherapy
Prof. Reinhard Dummer